Patents by Inventor Mark Lackner

Mark Lackner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
    Publication number: 20230064677
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Application
    Filed: August 2, 2022
    Publication date: March 2, 2023
    Applicant: Genentech, Inc
    Inventors: Mark LACKNER, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS
    Publication number: 20220305008
    Abstract: The present disclosure relates in part to methods for treating non-uveal melanoma cancers having GNAQ or GNA11 genetic mutations that include administering a PKC small molecule inhibitor.
    Type: Application
    Filed: January 7, 2020
    Publication date: September 29, 2022
    Inventors: John Knox, Mark Lackner, Zineb Mounir, Carol O'Brien
  • Use of human epididymis protein 4 (HE4) for assessing responsiveness of MUC 16-positive cancer treatment
    Patent number: 11440969
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 13, 2022
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • Genetic variations associated with drug resistance
    Patent number: 11021711
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: June 1, 2021
    Assignee: GENENTECH, INC.
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
    Publication number: 20190233538
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 1, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark LACKNER, Daniel MASLYAR, Yulei WANG, Walter DARBONNE, Eric HUMKE
  • GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE
    Publication number: 20180298387
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Application
    Filed: December 11, 2017
    Publication date: October 18, 2018
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • Genetic variations associated with drug resistance
    Patent number: 9879267
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: January 30, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • Compositions and methods for prostate cancer analysis
    Patent number: 9632091
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 25, 2017
    Assignee: GENENTECH, INC.
    Inventors: Siminder Atwal, Jo-Anne Hongo, Mark Lackner, Elizabeth Punnoose, Bonnee Rubinfeld, Rajesh Vij
  • COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS
    Publication number: 20160274116
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
    Type: Application
    Filed: October 21, 2015
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Siminder ATWAL, Jo-Anne HONGO, Mark LACKNER, Elizabeth PUNNOOSE, Bonnee RUBINFELD, Rajesh VIJ
  • GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE
    Publication number: 20110177099
    Abstract: Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.
    Type: Application
    Filed: March 12, 2009
    Publication date: July 21, 2011
    Inventors: Mark Lackner, Lukas C. Amler, Guy Cavet, Carol O'Brien, Ajay Pandita
  • Rabs as modifiers of the p53 pathway and methods of use
    Publication number: 20060084063
    Abstract: Human RAB genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of RAB are provided.
    Type: Application
    Filed: July 9, 2003
    Publication date: April 20, 2006
    Inventors: Michael Costa, Mark Maxwell, Mark Lackner, Tak Hung, Carol OBrien, Timothy Heuer, Kim Lickteig